Recent advances in emerging PCOS therapies

Area of Science:

• Reproductive Endocrinology
• Metabolic Disorders
• Neuroendocrinology

Background:

• Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by androgen excess and anovulatory infertility.
• PCOS is associated with significant comorbidities like obesity, hyperinsulinemia, and increased cardiovascular risk.
• The heterogeneous nature of PCOS phenotypes complicates clinical management.

Purpose of the Study:

• To review recent findings on emerging therapies for polycystic ovary syndrome (PCOS).
• To highlight novel treatment strategies addressing key PCOS manifestations.
• To provide an overview of advancements in managing PCOS symptoms and associated risks.

Main Methods:

• Literature review of recent research on PCOS therapies.
• Focus on pharmacological agents, neuroendocrine modulation, and metabolic interventions.
• Synthesis of findings on emerging treatment approaches.

Main Results:

• Emerging pharmacological agents effectively target androgen excess in PCOS.
• Modulation of kisspeptin signaling offers a new avenue for addressing neuroendocrine dysregulation.
• Novel insulin sensitizers show promise in combating peripheral metabolic dysfunction associated with PCOS.

Conclusions:

• Recent advancements offer promising new therapeutic options for PCOS.
• Targeting androgen excess, neuroendocrine pathways, and metabolic dysfunction are key strategies.
• These emerging therapies may improve clinical management and patient outcomes for PCOS.